RxDoctor Payments Data

Kamel Kamel, MD

Psychiatry · Irvine, CANPI 1811938541

Payments from drug & device makers

$1,348in general payments, 2019–2025

Across 20 payments — averaging $67.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$254
  • Acadia Pharmaceuticals Inc$244
  • Alkermes, Inc.$214
  • Johnson & Johnson$150
  • Neurocrine Biosciences, Inc.$125
  • Tris Pharma Inc$125
  • plus $237 from 5 others

What the payments were for

  • Food & beverage$1,33999%
  • Education$91%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,348 in reported general payments places this provider in the 75th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$1,632,266
Medicare patients
2,828
Services billed
32,784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega HafyeraPaliperidone Palmitate25$519,160
Invega SustennaPaliperidone Palmitate159$493,460
Invega TrinzaPaliperidone Palmitate30$301,035
Abilify MaintenaAripiprazole45$123,368
Aripiprazole OdtAripiprazole66$81,526
Aripiprazole525$25,802
Divalproex Sodium477$9,902
Quetiapine Fumarate382$6,549
Buspirone Hcl636$6,536
Memantine Hcl252$6,166
EliquisApixaban16$5,669
Mirtazapine271$5,601
Paliperidone ErPaliperidone36$4,266
Duloxetine Hcl285$3,958
Gabapentin258$3,429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$150$794,495189 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$254$123,36845 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Irvine

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →